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(Genesis and/or GEDEFO) and health-economists (universities/public entities). 
The questionnaire consisted of 36 items with a Likert rating scale of 9 points (9 
= full agreement). Consensus was considered when more than two-thirds of the 
responses were in the same tercile. Results: A total of 101 experts where invited 
(40.6% oncologists; 44.6% hospital pharmacists and 14.8% health-economists). 
81% and 67% questionnaires were retrieved in the first and second round, respec-
tively. Only two rounds were required as variability was less than 10% (delta CV 
7.1%). Internal consistency of the questionnaire was high (α C: 0.886), as was the 
correlation between the rounds (R of Spearman: 0.946) Consensus was attained 
in 29 items. Most experts agreed on: i) the need to improve scales and quality 
of life-related measurements (96%, CI95%= 90.7-98.8%); ii) the need for Health 
Authorities to define a cost-effectiveness threshold (91%, CI95%= 84.5-97.9%) and 
if a different one for “end of life treatments” is required (81%, CI95%= 71.7-90.3%); 
iii) the importance of considering cost-effectiveness data along with the budget 
impact of oncologic therapies (97%, CI95%= 93.1-99,0%); iv) the need to consider 
the societal perspective in the assessment of advanced cancer treatments (94%, 
CI95%= 88.5-99.7%). Lack of consensus was observed regarding the use of mean or 
median overall survival as best efficacy variable for IO therapies ConClusions: 
Consensus in both clinical and pharmaco-economic aspects was high among the 
different health professionals. Lack of agreement in specific questions suggests 
the need for further research on these new therapeutic options.
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objeCtives: In patients with bone metastases from solid tumours, denosumab 
(Dmab) subcutaneous (SC) injection represents an alternative formulation to zole-
dronic acid (Zol) intravenous (IV) infusion with a superior efficacy for skeletal-related 
events prevention. This observational Time and Motion study estimated treatment 
duration endpoints associated with Dmab SC injection and Zol IV use as monother-
apy. Methods: In the ambulatory setting of 3 Belgian hospitals, patients with bone 
metastases from solid tumours were observed during administration of SC Dmab 
or Zol IV. The following pre-defined tasks were recorded in military time: patient 
registration, drug preparation, IV catheter installation (one site additionally included 
routine blood sampling), IV/SC drug administration (IV: infusion connection until 
disconnection; SC: syringe filling and injection), material disposal, and post-treatment 
monitoring. Active healthcare professional (HCP) time associated with aforemen-
tioned pre-defined tasks was recorded using a stopwatch. Time endpoints measured 
for each treatment were total task time, total active HCP time, drug administration 
duration, and patient chair time. Data (mean) were analyzed per site and pooled using 
a random intercept model. Results: 44 Dmab SC and 29 Zol IV observations were 
collected. Pooled data across sites showed a mean duration of Dmab SC injection of 
1.4 minutes (min) and 29 min for Zol IV (95% time reduction). The mean total tasks 
time was 10.3 min for SC Dmab and 49.2 min for IV Zol (-79%). When Dmab SC was 
used, active HCP time was decreased by 54% (6.5 min for SC Dmab vs. 14.2 min for 
Zol IV). Mean patient chair time was 12.2 min for SC Dmab and 60.5 min for IV Zol 
(-80%). ConClusions: Dmab SC injection was associated with time savings in all 
endpoints measured. Using SC Dmab administration instead of Zol infusion could 
improve patient comfort and free up hospital capacity to treat patients in Belgium.
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objeCtives: Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available 
as a superior treatment option in patients with bone metastases from solid tumours, 
compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. 
Although Zol was the mainstay treatment for skeletal-related events prevention, 
Dmab provides an alternative formulation to IV infusions. This Time and Motion 
study was conducted in Italy to estimate treatment duration endpoints associated 
with Dmab SC and Zol IV use. Methods: Patients with bone metastases from solid 
tumours scheduled to receive Dmab SC or Zol IV monotherapy in the outpatient 
setting of 5 Italian hospitals were included. The following pre-defined tasks were 
recorded in military time: patient registration, IV catheter installation, IV/SC drug 
administration (IV: infusion connection until disconnection; SC: syringe filling and 
injection), and post-treatment monitoring. Active healthcare professional (HCP) time 
was recorded using a stopwatch. Time endpoints were total task time, total active 
HCP time, drug administration duration, and patient chair time. Data (mean) were 
analysed per site and pooled by country using a random intercept model. Results: 
A total of 85 observations were collected (50 Dmab SC and 35 Zol IV). Across sites, 
mean administration duration of Dmab SC was 3.4 minutes (min) and 15.9 min for 
Zol IV (-78%). The mean total task time was 9.9 min for Dmab SC and 31.2 min for Zol 
IV (-68%). Time savings associated with Dmab SC versus Zol IV were also reflected 
in the total active HCP time (7.2 min vs. 12.1 min, -41%) and patient chair time (8.1 
perception was highly modified by a number of factors, most significantly order of 
presentation of risks and benefits and comprehension of a drug’s risks and benefits. 
Showing the favourable effects first could halve the odds ratio of a more nega-
tive score, with all other factors held constant. Better comprehension always led 
to more positive perception. Other significant factors included negative mood at 
time of answering and number of other formats already shown, both leading to 
more negative answers. Impact of presentation type was highly dependent on the 
therapeutic area. ConClusions: The perception of a drug’s benefit-risk can be 
heavily impacted by how it is presented to the patient. These results underline the 
importance of using an understandable presentation format in the communication 
of benefits and risks of drugs in order to support patients to make informed deci-
sions regarding their treatment choice.
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objeCtives: Between 10 and 29% of lung cancer (LC) are supposed to be attribut-
able to occupational exposures. However, LC of occupational origin remains under-
reported. To improve the identification and compensation of occupational LC, we 
implemented at the Léon-Bérard Cancer Centre, a questionnaire-based process to 
systematically identify LC patients potentially exposed at the workplace and to be 
seen in an “occupational cancer” consultation. Selection was based on patients’ 
reporting of exposure to carcinogens or potentially exposed occupations. The aim 
of this study was to assess the cost of this innovative program. Methods: The 
cost assessment was performed prospectively. Three situations were analyzed: 
questionnaire returned by the patient (up to one reminder), consultation required 
(situation 1), questionnaire returned (up to one reminder), no consultation 
required (situation 2), questionnaire not returned (up to one reminder) (situation 
3). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Data on consumption of resources were collected from 
the questionnaire administration until the physician evaluation and occupational 
cancer declaration if any. Uncertainty was captured by one-way and probabilistic 
sensitivity analyses using a non-parametric bootstrap method. All costs were 
given in 2014 euros. Results: 310 patients were enrolled from March 2014 to 
May 2015. 9 patients without lung cancer were excluded. The measured costs per 
patient were in average € 179 (SD: 53) for situation 1 (n= 77), 40€ (SD 16) for situation 
2 (n= 82), and € 24 (SD: 7) for situation 3 (n= 142). Sensitivity analyses showed that 
the unit costs of physician and duration of consultations had a major role in the 
process’ costs. ConClusions: The implementation of our approach increased the 
identification and the compensation of occupational lung cancer. Our approach 
responds to the objectives of the National Cancer Plan and helps to improve the 
overall care of patients with cancer.
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objeCtives: The number of patients seeking cancer information over the internet 
is increasing. However, it is unknown what kind of information sources is available 
online in Japan, UK and USA. The objective of the study is to evaluate the informa-
tion sources related to breast cancer and to compare the information source among 
Japan, UK and USA. Methods: We identified top-rated 20 information sites and 
the number of advertisements on the initial screen by using a key word as “Breast 
cancer” on Yahoo and Google sites in Japan, UK and USA. Information sources were 
defined and categorized into six kinds of information organizers; public institutes, 
academic associations, NGO/NPOs, information portal, advertisements, and corpo-
rate sponsored sites. The each information source was categorized by two evalu-
ators independently. Third evaluator reconciled and decided the category of the 
information source if evaluation results were not identical between two evaluators. 
The proportion of internet sources by six categories was calculated and compared 
among three countries. Results: In Japan, the proportion of information sources 
by public institutions and academic associations was 30%. Less than 10% of infor-
mation sources were by NGO/NPOs. More than half of information sources were 
advertisements. In UK, 70% of information sources were provided by NGO/NPOs 
whereas less than 20% of information sources were advertisement. In USA, 30% 
of information sources were by academic institutions whereas more than 50% of 
information sources were by information portal. ConClusions: This comparative 
survey provides an overview of information sources related to breast cancer avail-
able on the internet. The number of top-rated information sites by public institutes, 
academic associations was low compared to UK and USA. There were a few informa-
tion sources by NGO/NPO in Japan.
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objeCtives: Clinical and health-economic criteria to accurately assess the 
value of new immuno-oncology (IO) drugs are currently undetermined. The aim 
of this study was to assess the current knowledge about these criteria among 
the Spanish scientific community. Methods: The Delphi method was used to 
survey a multi-disciplinary group of Spanish oncologists [melanoma, lung, or 
genitourinary-specialists (hospital/regional managers)], hospital pharmacists 
